Best of 2024: Good Clinical Practice Recommendations on Glucocorticoid Withdrawal and Adrenal Insufficiency

Save

Glucocorticoids are widely prescribed as anti-inflammatory and immunosuppressive agents. This results in at least 1% of the population using chronic glucocorticoid therapy being at risk for glucocorticoid-induced adrenal insufficiency. This risk is dependent on the dose, duration and potency of the glucocorticoid, route of administration, and individual susceptibility.

Best of 2024: Inadequate Zoster Vaccination in Immunocompromised Patients

Save

A VA study of shows that recombinant zoster vaccine (RZV) vaccination in immunocompromised patients or those receiving immunosuppressive medications is insufficient, given these are high risk individuals.

Bah Humbug Vitamin D (12.20.2024)

Save

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

Best of 2024: Determinants of Gout Flares

Save

Approximately 12 million US adults in the US have gout. Two recent literature reports in JAMA and Arthritis Care & Research highlight contributors to gout flares.

ICYMI: Are Emulation Trials a Fantasy?

Save

Are emulation ‘trials’ helpful, despite the biases that occur with observational data, or do they truly mimic the results of randomized controlled trials (RCTs)?

ICYMI: Say Goodbye to Methotrexate in PMR?

Save

For decades, glucocorticoids (GCs) have formed the backbone of polymyalgia rheumatica (PMR) management.

Drug-Free Remission in Giant Cell Arteritis is Uncommon

Save

ACR24: Rheumatology Roundup

Save

Join Drs. Jack Cush and Artie Kavanaugh as they review 15+ presentations and abstracts from the 2024 ACR Convergence meeting in Washington, DC.

Maximizing DMARDs to Strive for Steroid-Free Remission in RA

Save

In 1950, three scientists were awarded the Nobel Prize for their groundbreaking discovery of steroids, heralded at the time as a "miracle cure" for rheumatoid arthritis (RA).

Is Your Practice Up to Date? New Guidelines for SLE Nephritis

Save

Randomized controlled trials (RCTs) drive guidelines; guidelines drive clinical practice. Because updated guidelines lag trials by many years and dissemination of guidelines takes additional time, rheumatologists often practice “behind the data.” The 2024 ACR Guidelines for the Management of SLE Nephritis reaffirmed many of our typical practice patterns, including hydroxychloroquine for all, renin/angiotensin blockade, and favoring mycophenolate mofetil over cyclophosphamide.

Methotrexate to Prevent RA, Clear as Mud

Save

Intervention in individuals predisposed to develop RA, with a holy grail of prevention of RA, has long been a hot topic. The 4-year results of the TREAT EARLIER study, presented at Tuesday’s oral abstract session, show that methotrexate appears to prevent the development of RA in high risk ACPA- patients.